The University of Colorado Cancer Center is a """"""""Center' within the School of Medicine at the University of Colorado Health Sciences Center. The Cancer Center goals are: 1) to contribute through coordinated research, clinical, control and educational activities effort to the eventual elimination of cancer as a human health problem, and 2) to provide the citizens of the State of Colorado and the Rocky Mountain region with state-of-the-art cancer research, therapy, control and educational programs. The Cancer Center serves 6 million people in Colorado and the 7 surrounding states in the Rocky Mountain region. The 190 Cancer Center members have more than $21 million (annual direct costs) in peer reviewed grants and contracts relating to the cancer problem. Cancer Center members provide care to approximately one-third of the cancer population in the region and enter more than 400 patients on cancer clinical trials each year. The Cancer Center enters an increasing number of patients of clinical trials emphasizing novel trials of the Center and high priority trials of the National Cancer Institute. The majority of cancer educational and control programs in the region are organized by Cancer Center members. The Center provides the major centralized support for these functions through its 10 shared """"""""core"""""""" facilities in Biostatistics, Clinical Investigations, Cytogenetics, Fermentation, Flow Cytometry, Histopathology/Tissue Procurement, Laboratory Animals/Transgenic Animals, Macromolecular Resources, Radiological Sciences and Tissue Culture/Monoclonal Antibodies. The Cancer Center has 14 institutional members including the Health Sciences Center schools, affiliated hospitals and other institutions with a primary focus in cancer. The chief executive officers of these organizations form the Cancer Center Board which assures coordination of the cancer effort in the region. The Cancer Center has four major program divisions: Basic Research, Clinical Activities, Education and Control. The Basic Research and Clinical Activities Divisions are divided into: Immunology; Molecular Biology; Growth Regulation; Cell Surface; Hormones and Cancer; Chromosomes, Mutation and Carcinogenesis; Medical Oncology; Surgical Oncology; Radiation Oncology; Nursing Oncology; and Pediatric Oncology program areas. The primary planning and operational decisions of the Cancer Center are made by the Management Committee which consists of the Director, Deputy Director, Associate Directors and Program Leaders. The University of Colorado Cancer Center has become the leader for the interdisciplinary study of cancer in the Rocky Mountain Region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-05
Application #
3101850
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1988-03-01
Project End
1995-02-28
Budget Start
1992-05-11
Budget End
1993-02-28
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Ye, Haobin; Adane, Biniam; Khan, Nabilah et al. (2018) Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell 34:659-673.e6
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464

Showing the most recent 10 out of 1634 publications